Saskatchewan

Recruiting location in the Saskatchewan:

• Regina – Allan Blair Cancer Centre (Mussawar Iqbal, mussawar.iqbal@saskcancer.ca)
• Saskatoon – Saskatoon Cancer Centre (Shahid Ahmed, shahid.ahmed@saskcancer.ca)

ID Number: NCT02773524

Links:

• Clinical Trials.gov

Description: This study is looking to determine if regorafenib improves survival in patients with advanced gastro-oesophageal carcinoma.

A: Regorafenib

B: Placebo

Intervention: Regorafenib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.

Can I consider participating?

• YES: patients who have advanced (metastatic or locally recurrent) gastro-oesophageal carcinoma that has not responded to minimum of 2 lines of prior anti-cancer therapy
• NO: patients who have malabsorption syndromes, poorly-controlled hypertension, significant active infection